Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 8, 2015, Pages 338.e9-338.e17

  Andersen, Sigve ^a,b   Solstad, Ørjan ^b   Moi, Line ^a,b   Donnem, Tom ^a,b   Eilertsen, Marte ^a   Nordby, Yngve ^a,b   Ness, Nora ^a   Richardsen, Elin ^a,b   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

MCT1; MCT4; Monocarboxylate transporter; Prostate cancer; Stroma

Indexed keywords

BIOLOGICAL MARKER; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; COTRANSPORTER; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SLC16A4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BIOCHEMICAL RECURRENCE; CANCER CELL; CANCER PROGNOSIS; CLINICAL EVALUATION; COHORT ANALYSIS; CORRELATION ANALYSIS; EPITHELIUM; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MIDDLE AGED; MOLECULAR BIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STROMA; TISSUE MICROARRAY; WARBURG EFFECT; CELL PROLIFERATION; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; HUMANS; MALE; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; SYMPORTERS;

EID: 84937523781     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.013     Document Type: Article

References (37)

1. van der Kwast T.H., Roobol M.J. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013, 10:473-482.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
3. Hayes J.H., Barry M.J. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. J Am Med Assoc 2014, 311:1143-1149.
4. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437.
5. Sanita P., Capulli M., Teti A., Galatioto G.P., Vicentini C., Chiarugi P., et al. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer 2014, 14:154.
6. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
7. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
8. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942.
9. Fiaschi T., Marini A., Giannoni E., Taddei M.L., Gandellini P., De D.A., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 2012, 72:5130-5140.
10. Pertega-Gomes N., Baltazar F. Lactate transporters in the context of prostate cancer metabolism: what do we know?. Int J Mol Sci 2014, 15:18333-18348.
11. Sonveaux P., Copetti T., De Saedeleer C.J., Vegran F., Verrax J., Kennedy K.M., et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One 2012, 7:e33418.
12. Kim H.S., Masko E.M., Poulton S.L., Kennedy K.M., Pizzo S.V., Dewhirst M.W., et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int 2012, 110:1062-1069.
13. Pertega-Gomes N., Vizcaino J.R., Miranda-Goncalves V., Pinheiro C., Silva J., Pereira H., et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011, 11:312.
14. Pertega-Gomes N., Vizcaino J.R., Attig J., Jurmeister S., Lopes C., Baltazar F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 2014, 14:352.
15. Eilertsen M., Andersen S., Al-Saad S., Kiselev Y., Donnem T., Stenvold H., et al. Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival. PLoS One 2014, 9:e105038.
16. Andersen S., Richardsen E., Nordby Y., Ness N., Storkersen O., Al-Shibli K., et al. Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol 2014, 14:49.
17. Giatromanolaki A., Koukourakis M.I., Koutsopoulos A., Mendrinos S., Sivridis E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther 2012, 13:1284-1289.
18. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
19. Pellerin L., Pellegri G., Bittar P.G., Charnay Y., Bouras C., Martin J.L., et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci 1998, 20:291-299.
20. Johnson M.T., Freeman E.A., Gardner D.K., Hunt P.A. Oxidative metabolism of pyruvate is required for meiotic maturation of murine oocytes in vivo. Biol Reprod 2007, 77:2-8.
21. Vaupel P., Kelleher D.K. Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol 2013, 765:299-305.
22. Martinez-Outschoorn U.E., Balliet R.M., Rivadeneira D.B., Chiavarina B., Pavlides S., Wang C., et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276.
23. Ord J.J., Streeter E.H., Roberts I.S., Cranston D., Harris A.L. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br J Cancer 2005, 93:346-354.
24. Pinheiro C., Longatto-Filho A., Azevedo-Silva J., Casal M., Schmitt F.C., Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012, 44:127-139.
25. Baltazar F., Pinheiro C., Morais-Santos F., Azevedo-Silva J., Queiros O., Preto A., et al. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 2014, 29:1511-1524.
26. Mitrakas A.G., Kalamida D., Koukourakis M.I. Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity. Anticancer Drugs 2014, 25:1182-1191.
27. Zhang A., Yan G., Han Y., Wang X. Metabolomics approaches and applications in prostate cancer research. Appl Biochem Biotechnol 2014, 174:6-12.
28. Sotgia F., Martinez-Outschoorn U.E., Lisanti M.P. Cancer metabolism: new validated targets for drug discovery. Oncotarget 2013, 4:1309-1316.
29. Teicher B.A., Linehan W.M., Helman L.J. Targeting cancer metabolism. Clin Cancer Res 2012, 18:5537-5545.
30. Mohamad H., McNeill G., Haseen F., N'Dow J., Craig L.C., Heys S.D. The effect of dietary and exercise interventions on body weight in prostate cancer patients: a systematic review. Nutr Cancer 2014, 25:1-18.
31. Vidal A.C., Williams C.D., Allott E.H., Howard L.E., Grant D.J., McPhail M., et al. Carbohydrate intake, glycemic index and prostate cancer risk. Prostate 2014, 75:430-439.
32. Patel V.H. Nutrition and prostate cancer: an overview. Expert Rev Anticancer Ther 2014, 14:1295-1304.
33. Caso J., Masko E.M., Ii J.A., Poulton S.H., Dewhirst M., Pizzo S.V., et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate 2013, 73:449-454.
34. Masko E.M., Thomas J.A., Antonelli J.A., Lloyd J.C., Phillips T.E., Poulton S.H., et al. Low-carbohydrate diets and prostate cancer: how low is low enough?. Cancer Prev Res (Phila) 2010, 3:1124-1131.
35. Lemanne D., Cassileth B., Gubili J. The role of physical activity in cancer prevention, treatment, recovery, and survivorship. Oncology (Williston Park) 2013, 27:580-585.
36. Wolin K.Y., Stoll C. Physical activity and urologic cancers. Urol Oncol 2012, 30:729-734.
37. Martinez-Outschoorn U., Sotgia F., Lisanti M.P. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol 2014, 41:195-216.